With obesity demonstrating mortality rates comparable to cigarette smoking and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches. Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.